From The Web / AHA 2020: RIVER Shows Rivaroxaban Safe for Patients with Bioprosthetic Valves
Results from the RIVER trial reveal important new information for the treatment of atrial fibrillation in patients with bioprosthetic mitral valves.
Source: Duke Clinical Research Institute